Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 61
Filtrar
2.
Hautarzt ; 66(10): 753-6, 2015 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-26253115

RESUMEN

Nonablative photothermolysis has become an established technique in laser dermatology. It is mainly used for restructuring dermal connective tissue in order to treat, for example, acne scars or solar elastosis. It is also applied to the treatment of melasma and other benign cutaneous pigment disorders. This article discusses various indications in light of published observations and with regard to practical considerations.


Asunto(s)
Acné Vulgar/terapia , Cicatriz/terapia , Técnicas Cosméticas , Terapia por Luz de Baja Intensidad/métodos , Trastornos de la Pigmentación/terapia , Estrías de Distensión/terapia , Fraccionamiento de la Dosis de Radiación , Medicina Basada en la Evidencia , Humanos , Resultado del Tratamiento
4.
Hautarzt ; 59(7): 579-89; quiz 590, 2008 Jul.
Artículo en Alemán | MEDLINE | ID: mdl-18535811

RESUMEN

Acne is treated according to the clinical picture and the pathophysiologically relevant mechanisms, such as seborrhea, follicular hyperkeratosis, P. acnes colonisation,and inflammation. In mild forms of acne, topical therapy is most appropriate. Comedonal acne can be treated with topical retinoids; papulopustular acne with a combination of retinoids and topical antimicrobial substances (benzoyl peroxide, antibiotics, or azelaic acid). Moderate forms or those with extrafacial involvement can be treated with oral antibiotics combined with topical retinoids or benzoyl peroxide. Acne conglobata and other severe manifestations are treated with oral isotretinoin. Women are also treated with oral contraceptives containing anti-androgenic progestins. If inflammation is prominent, initial short term treatment with oral glucocorticoids is helpful. Second-line agents include oral zinc or dapsone. Following successful treatment, topical retinoids are suitable for maintenance therapy.


Asunto(s)
Acné Vulgar/tratamiento farmacológico , Antagonistas de Andrógenos/uso terapéutico , Antibacterianos/uso terapéutico , Peróxido de Benzoílo/uso terapéutico , Retinoides/uso terapéutico , Fármacos Dermatológicos/uso terapéutico , Humanos
5.
Hautarzt ; 59(6): 503-12; quiz 511, 2008 Jun.
Artículo en Alemán | MEDLINE | ID: mdl-18488182

RESUMEN

Seborrhea, follicular hyperkeratosis, propionibacteria, and inflammatory reactions are the most important factors leading to acne. The combination of increased sebum producation and follicular hyperkeratosis facilitates an increased growth of Propionibacterium acnes. Its metabolic products lead to follicular inflammation and, in extreme cases, even to perifollicular abscesses. Sebum production is influenced by androgens, so that abnormalities in androgen levels can produce seborrhea and acne. Follicular hyperkeratosis may be triggered by a relative deficiency in linoleic acid, peroxides from sebum components, and especially by inflammatory mediators such as interleukin-1. Bacterial metabolic products such as lipases, proteases, or chemotactic factors lead to the perifollicular inflammation. This inflammation is not only a response to other pathogenetic factors, but also a cause of acne. An initial mild perifollicular inflammation can induce comedogenesis via a variety of mediators. The influence of dietary factors on the initiation and course of acne has recently received increased recognition. A connection has been postulated between acne and a high nutrients with glycemic index, as well as with milk products.


Asunto(s)
Acné Vulgar/fisiopatología , Infecciones por Bacterias Grampositivas/fisiopatología , Propionibacterium acnes , Acné Vulgar/etiología , Acné Vulgar/patología , Andrógenos/fisiología , Biopsia , Enfermedad de Darier/complicaciones , Enfermedad de Darier/patología , Enfermedad de Darier/fisiopatología , Infecciones por Bacterias Grampositivas/etiología , Infecciones por Bacterias Grampositivas/patología , Humanos , Queratosis Seborreica/complicaciones , Queratosis Seborreica/patología , Queratosis Seborreica/fisiopatología , Propionibacterium acnes/crecimiento & desarrollo , Factores de Riesgo , Sebo/metabolismo , Piel/patología
6.
J Eur Acad Dermatol Venereol ; 22(6): 722-8, 2008 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-18312326

RESUMEN

BACKGROUND: It has been shown that varicella zoster virus (VZV) and herpes simplex virus (HSV) can co-localize to the same sensory ganglion. However, only a few case reports on VZV/HSV co-infections exist. Objective To identify and characterize patients with concurrent VZV and HSV infection at the same body site. SUBJECTS/METHODS: In 1718 patients, the presence of VZV and HSV in suspicious skin lesions was investigated by polymerase chain reaction analysis. Clinical characteristics of co-infected patients were compared with matched control patients infected with either VZV or HSV. The data are discussed in the context of an extensive review of the literature. RESULTS: Twenty (1.2%) of 1718 patients were infected with both VZV and HSV at the same body site. The mean age was 54 years (range, 2-83). The clinical diagnosis was zoster in 65%, herpes simplex in 20%, varicella in 10% and erythema multiforme in 5% of cases. The trigeminus region was affected in 60% and the trunk in 25%. Involvement of the head was most commonly associated with a severe course of disease and with older age. CONCLUSION: Simultaneous VZV/HSV infection is rare but can occur in immunocompetent patients, which is often overlooked. The majority of cases is localized to the trigeminus region and affects elderly people.


Asunto(s)
Varicela/complicaciones , Herpes Zóster/complicaciones , Inmunocompetencia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Secuencia de Bases , Varicela/diagnóstico , Niño , Preescolar , Cartilla de ADN , Diagnóstico Diferencial , Femenino , Herpes Zóster/diagnóstico , Herpesvirus Humano 1/genética , Herpesvirus Humano 1/aislamiento & purificación , Herpesvirus Humano 3/genética , Herpesvirus Humano 3/aislamiento & purificación , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Estudios Retrospectivos
7.
Endoscopy ; 40(2): 106-9, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18197583

RESUMEN

BACKGROUND AND STUDY AIMS: We aimed to determine the feasibility of obtaining selective fluorescence of precancerous/cancerous lesions in the colon with a new fluorescence video endoscope system in combination with the selective photosensitizer precursor hexaminolevulinate (HAL), and to carry out a dose-finding study with evaluation of the optimal dose and application time. PATIENTS AND METHODS: 12 patients with colorectal lesions underwent sensitization with locally applied HAL enemas in two concentrations (0.8 mmol and 1.6 mmol). The examination was conducted either 30 or 60 minutes after rectal administration of the sensitizer, using a special light source capable of delivering either white or blue excitation light. Red fluorescence induced by illumination with blue light was detected via a prototype fluorescence video colonoscope. Biopsies were taken from suspicious areas found with white or blue light. Corresponding endoscopic, fluorescence, and microscopic findings were compared. RESULTS: Using histological findings as the gold standard, 52/53 of the premalignant/malignant lesions showed red fluorescence under the photodynamic diagnosis (PDD) examination; 38/53 were detected with white-light endoscopy. The PDD mode showed 28 % more polyps than did white-light endoscopic imaging. The greatest fluorescence intensity in precancerous lesions was found with retention for 60 minutes of 500 ml of 1.6 mmol HAL. CONCLUSIONS: Administration of HAL enema induces selective lesion fluorescence and increases the lesion detection rate in patients with colorectal adenoma and early carcinoma.


Asunto(s)
Ácido Aminolevulínico/análogos & derivados , Neoplasias del Colon/patología , Pólipos del Colon/diagnóstico , Colonoscopía/métodos , Fármacos Fotosensibilizantes , Lesiones Precancerosas/diagnóstico , Anciano , Biopsia con Aguja , Neoplasias del Colon/prevención & control , Pólipos del Colon/patología , Diagnóstico Precoz , Estudios de Factibilidad , Femenino , Fluorescencia , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Lesiones Precancerosas/patología , Sensibilidad y Especificidad
8.
Cell Death Differ ; 14(4): 818-29, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17110957

RESUMEN

The urokinase-type plasminogen activator receptor (uPAR) is involved in several biological processes, including proteolysis, adhesion, migration and inflammation. Increased expression of uPAR is associated with metastasis in several tumor types. We studied the biological role of uPAR in melanoma and found that inhibition of uPAR via RNA interference induced massive death in three different metastatic cell lines. Annexin-V staining and caspase activation analysis revealed induction of the mitochondrial apoptotic pathway. The expression of members of the Bcl-2 family (Bax, Bcl-2, Bak and Bcl-x(L)) was changed in a pro-apoptotic manner. uPAR inhibition induced the expression of the tumor suppressor p53 and of its downstream target gene p21. Inhibition of p53 rescued cells from apoptosis indicating that p53 was critical for apoptosis induction. Apoptosis was observed in melanoma cells carrying activating BRAF mutations and occurred in the presence of extracellular signal-regulated kinase (ERK) phosphorylation. uPAR can activate focal adhesion kinase (FAK), which is implicated in adhesion-dependent tumor cell survival. However, inhibition of FAK did not induce apoptosis. Our data suggest a new function of uPAR acting as a survival factor for melanoma by downregulating p53. Inhibition of uPAR induces a pro-apoptotic signalling pathway via p53 that is independent of ERK or FAK signalling. These findings may offer new treatment strategies for metastatic melanoma.


Asunto(s)
Apoptosis , Melanoma/metabolismo , Receptores de Superficie Celular/antagonistas & inhibidores , Neoplasias Cutáneas/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/fisiología , Biomarcadores de Tumor/metabolismo , Proliferación Celular , Supervivencia Celular , Regulación hacia Abajo/genética , Proteína-Tirosina Quinasas de Adhesión Focal/metabolismo , Humanos , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , ARN Interferente Pequeño/genética , Receptores de Superficie Celular/genética , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Transducción de Señal , Células Tumorales Cultivadas
9.
Clin Exp Dermatol ; 31(1): 51-3, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16309481

RESUMEN

Current treatments for genital condylomata are not completely satisfactory, as they fail to clear lesions in a proportion of patients, and relapses after successful treatment are frequently seen. Photodynamic therapy (PDT) using topical 5-aminolaevulinic acid (5-ALA) has been suggested as a novel treatment option. We performed a small open study using topical 5-ALA and red light (630 nm) in nine men with genital condylomata and a history of at least one previous unsuccessful conventional treatment. Complete cure was achieved in three patients, one of whom experienced a relapse after 3 weeks. Three patients showed partial responses, and three showed no response. Based on the currently available evidence, PDT is a viable treatment option for selected cases that fail to respond to other therapies.


Asunto(s)
Condiloma Acuminado/tratamiento farmacológico , Enfermedades de los Genitales Masculinos/tratamiento farmacológico , Fotoquimioterapia/métodos , Administración Tópica , Adulto , Ácido Aminolevulínico/administración & dosificación , Condiloma Acuminado/patología , Enfermedades de los Genitales Masculinos/patología , Humanos , Masculino , Recurrencia , Resultado del Tratamiento
10.
Hautarzt ; 56(11): 1027-32, 2005 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-16200418

RESUMEN

In recent years, a number of studies have evaluated the treatment of acne using electromagnetic waves, such as lasers, photodynamic therapy, visible light or radio waves. While the efficacy of laser treatment is still uncertain, photodynamic therapy shows promising results, but with marked side-effects, as destruction of sebaceous glands. Treatment with blue light (405-420 nm wavelength) also appears effective and can be regarded as an treatment option for inflammatory acne.


Asunto(s)
Acné Vulgar/terapia , Terapia por Luz de Baja Intensidad/métodos , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Humanos , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Resultado del Tratamiento
11.
Hautarzt ; 56(11): 1013-7, 2005 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-16215770

RESUMEN

Several pathogenic factors contribute to the development of acne, among them, seborrhea, follicular hyperkeratosis, propionibacteria, and inflammatory events. This article reviews current knowledge of these pathogenic factors.


Asunto(s)
Acné Vulgar/patología , Acné Vulgar/fisiopatología , Dermatitis/patología , Dermatitis/fisiopatología , Hiperqueratosis Epidermolítica/patología , Hiperqueratosis Epidermolítica/fisiopatología , Propionibacterium acnes , Acné Vulgar/microbiología , Dermatitis/microbiología , Humanos , Hiperqueratosis Epidermolítica/microbiología
12.
Br J Dermatol ; 153(4): 733-9, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16181453

RESUMEN

BACKGROUND: Besides the direct DNA-damaging effects of ultraviolet (UV) radiation on cells, indirect effects on the microenvironment of the skin may facilitate melanoma development. A stimulation of growth factor production by cells in the immediate environment of melanocytes may lead to a paracrine activation and proliferation of melanocytes that in turn become more susceptible to transformation. OBJECTIVES: We investigated whether the expression of growth factors for melanocytes can be modulated in keratinocytes and fibroblasts by UVA or UVB. METHODS: After irradiation with different doses of UVA or UVB, protein expression of basic fibroblast growth factor (bFGF), endothelin (ET)-1, transforming growth factor (TGF)-beta1, platelet-derived growth factor (PDGF)-AA, stem cell factor (SCF) and hepatocyte growth factor (HGF) was analysed by quantitative enzyme-linked immunosorbent assay. The mRNA expression of bFGF and ET-1 was analysed by quantitative real-time reverse transcriptase-polymerase chain reaction. RESULTS: In keratinocytes, UVB and UVA increased bFGF protein levels up to 2.6-fold. This increase was paralleled by elevated mRNA levels. UVB also induced ET-1 protein up to 1.8-fold, while UVA led to an 80% decrease. Secreted TGF-beta1 and PDGF-AA were downregulated by UVA by less than 50%, while there was no significant alteration by UVB. Secreted SCF was not changed significantly by UVA or UVB. In fibroblasts, bFGF protein levels were increased 11-64-fold by UVA and 34-61-fold by UVB. This was paralleled by elevated mRNA levels for bFGF up to 2.7-fold. HGF protein was stimulated by UVA up to 2.8-fold and by UVB up to 6.7-fold, while TGF-beta1 protein was increased up to 2.7-fold by UVB and 1.7-fold by UVA. CONCLUSIONS: UVA and UVB can stimulate and inhibit the production of growth factors for melanocytes in keratinocytes and fibroblasts dependent on the cell type and wavelength. We show for the first time that UVA and UVB can activate bFGF, HGF and TGF-beta1 in fibroblasts, while bFGF was the most inducible factor both in fibroblasts and in keratinocytes. The induction of bFGF and HGF in fibroblasts by UVA suggests that stroma cells in the dermis may be involved in the UV activation of melanocytes via paracrine ways and thus promote melanoma development.


Asunto(s)
Fibroblastos/efectos de la radiación , Sustancias de Crecimiento/efectos de la radiación , Queratinocitos/efectos de la radiación , Rayos Ultravioleta , Células Cultivadas , Niño , Preescolar , Endotelina-1/metabolismo , Endotelina-1/efectos de la radiación , Ensayo de Inmunoadsorción Enzimática/métodos , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Factor 2 de Crecimiento de Fibroblastos/efectos de la radiación , Fibroblastos/metabolismo , Sustancias de Crecimiento/metabolismo , Factor de Crecimiento de Hepatocito/metabolismo , Factor de Crecimiento de Hepatocito/efectos de la radiación , Humanos , Queratinocitos/metabolismo , Masculino , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Factor de Células Madre/metabolismo , Factor de Células Madre/efectos de la radiación , Factor de Crecimiento Transformador beta/metabolismo , Factor de Crecimiento Transformador beta/efectos de la radiación , Factor de Crecimiento Transformador beta1
13.
Clin Exp Dermatol ; 30(4): 379-81, 2005 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-15953075

RESUMEN

Narrow band (311 nm) ultraviolet B (NB-UVB) has been shown to be a safe and effective treatment for psoriasis and other inflammatory skin diseases. We have therefore employed NB-UVB in the treatment of small plaque parapsoriasis (SPP) since 1996. All patients (16/16) responded with complete remission of the disease after a mean number of 32.8 exposures and a mean total dose of 35.4 J/cm2. Unwanted side-effects were rare (3.3%) and always mild. Relapse of the disease occurred after an average of 29 weeks in those patients who came for follow-up visits. Therefore, NB-UVB is an effective, comparably safe and convenient alternative to psoralen and ultraviolet A therapy or other treatment modalities in the suppression of SPP.


Asunto(s)
Parapsoriasis/radioterapia , Terapia Ultravioleta/métodos , Adulto , Anciano , Fraccionamiento de la Dosis de Radiación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Estudios Retrospectivos , Resultado del Tratamiento , Terapia Ultravioleta/efectos adversos
14.
Br J Dermatol ; 148(6): 1263-6, 2003 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12828760

RESUMEN

Seborrhoea is one pathogenic factor for acne. Androgens induce sebum production, and excess androgen may provoke or aggravate acne. In women an androgen disorder is frequently suspected when acne is accompanied by hirsutism or menstrual irregularities. In men acne may be the only symptom of androgen excess. We report three male acne patients in whom hormonal screening revealed irregularities of androgen metabolism suggestive of late-onset congenital adrenal hyperplasia and who benefitted from low-dose glucocorticoids. Disorders of androgen metabolism may influence acne not only in women, but also in men, and these patients may benefit from low-dose glucocorticoid therapy.


Asunto(s)
Acné Vulgar/etiología , Hiperplasia Suprarrenal Congénita/complicaciones , Acné Vulgar/tratamiento farmacológico , Administración Tópica , Adolescente , Hiperplasia Suprarrenal Congénita/tratamiento farmacológico , Antiinflamatorios/uso terapéutico , Glucocorticoides , Humanos , Masculino , Metilprednisolona/uso terapéutico
15.
Hautarzt ; 53(10): 650-1, 2002 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-12297945

RESUMEN

Lichen planus is a T cell mediated papular skin disease. Chronic hepatic disorders, especially chronic hepatitis, have been found to be associated with lichen planus. Recently, it has been recognized that lichen planus can be triggered by hepatitis B vaccination. Here we report on cases of lichen planus triggered by vaccination and review the current literature. Hepatitis B vaccination is being increasingly used and should be considered as a possible trigger of lichen planus.


Asunto(s)
Vacunas contra Hepatitis B/efectos adversos , Liquen Plano/etiología , Adolescente , Niño , Diagnóstico Diferencial , Humanos , Lactante , Liquen Plano/diagnóstico , Factores de Riesgo
16.
Biol Chem ; 382(8): 1197-205, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11592401

RESUMEN

Urokinase-type plasminogen activator (uPA) represents a central molecule in pericellular proteolysis and is implicated in a variety of physiological and pathophysiological processes such as tissue remodelling, wound healing, tumor invasion, and metastasis. uPA binds with high affinity to a specific cell surface receptor, uPAR (CD87), via a well defined sequence within the N-terminal region of uPA (uPA19-31). This interaction directs the proteolytic activity of uPA to the cell surface which represents an important step in tumor cell proliferation, invasion, and metastasis. Due to its fundamental role in these processes, the uPA/uPAR-system has emerged as a novel target for tumor therapy. Previously, we have identified a synthetic, cyclic, uPA-derived peptide, cyclo19,31uPA19-31, as a lead structure for the development of low molecular weight uPA-analogues, capable of blocking uPA/uPAR-interaction [Burgle et al., Biol. Chem. 378 (1997), 231-237]. We now searched for peptide variants of cyclo19,31uPA19-31 with elevated affinities for uPAR binding. Among other tasks, we performed a systematic D-amino acid scan of uPA19-31, in which each of the 13 L-amino acids was individually substituted by the corresponding D-amino acid. This led to the identification of cyclo19,31[D-Cys19]-uPA19-31 as a potent inhibitor of uPA/uPAR-interaction, displaying only a 20 to 40-fold lower binding capacity as compared to the naturally occurring uPAR-ligands uPA and its amino-terminal fragment. Cyclo19,31[D-Cys19]-uPA19-31 not only blocks binding of uPA to uPAR but is also capable of efficiently displacing uPAR-bound uPA from the cell surface and to inhibit uPA-mediated, tumor cell-associated plasminogen activation and fibrin degradation. Thus, cyclo19,31[D-Cys19]-uPA19-31 represents a promising therapeutic agent to significantly affect the tumor-associated uPA/uPAR-system.


Asunto(s)
Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/farmacología , Péptidos Cíclicos/síntesis química , Péptidos Cíclicos/farmacología , Receptores de Superficie Celular/metabolismo , Activador de Plasminógeno de Tipo Uroquinasa/antagonistas & inhibidores , Activador de Plasminógeno de Tipo Uroquinasa/síntesis química , Activador de Plasminógeno de Tipo Uroquinasa/farmacología , Sustitución de Aminoácidos , Unión Competitiva , Membrana Celular/metabolismo , Células Cultivadas , Fibrina/metabolismo , Humanos , Concentración 50 Inhibidora , Fragmentos de Péptidos/metabolismo , Péptidos Cíclicos/metabolismo , Plasminógeno/metabolismo , Receptores de Superficie Celular/efectos de los fármacos , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Relación Estructura-Actividad , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo
17.
J Allergy Clin Immunol ; 108(2): 221-8, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11496238

RESUMEN

BACKGROUND: Rhinoviruses have been recently associated with the majority of asthma exacerbations for which current therapy is inadequate. Intercellular adhesion molecule 1 (ICAM-1) has a central role in airway inflammation in asthma, and it is the receptor for 90% of rhinoviruses. Rhinovirus infection of airway epithelium induces ICAM-1. Desloratadine and loratadine are compounds belonging to the new class of H(1)-receptor blockers. Anti-inflammatory properties of antihistamines have been recently documented, although the underlying molecular mechanisms are not completely defined. OBJECTIVE: We have investigated the effects of desloratadine and loratadine on rhinovirus-induced ICAM-1 expression, mRNA upregulation, and promoter activation. METHODS: Cultured primary bronchial or transformed (A549) respiratory epithelial cells were pretreated with desloratadine and loratadine for 16 hours and infected with rhinovirus type 16 for 8 hours. ICAM-1 surface expression was evaluated with flow cytometry, and ICAM-1 mRNA was evaluated with specific RT-PCR. In A549 cells promoter activation was evaluated with a chloramphenicol acetyltransferase assay, and binding activity of nuclear factor kappa B in nuclear extracts was evaluated with an electrophoretic mobility shift assay. RESULTS: Desloratadine and loratadine (0.1-10 micromol/L) inhibited rhinovirus-induced ICAM-1 upregulation in both primary bronchial or transformed (A549) respiratory epithelial cells. In A549 cells the 2 compounds showed a dose-dependent inhibition with similar efficacy (inhibitory concentration of 50%, 1 micromol/L). Desloratadine and loratadine also inhibited ICAM-1 mRNA induction caused by rhinovirus infection in a dose-dependent manner, and they completely inhibited rhinovirus-induced ICAM-1 promoter activation. Desloratadine also inhibited rhinovirus-induced nuclear factor kappa B activation. Desloratadine and loratadine had no direct effect on rhinovirus infectivity and replication in cultured epithelial cells. CONCLUSION: These effects are unlikely to be mediated by H(1)-receptor antagonism and suggest a novel mechanism of action that may be important for the therapeutic control of virus-induced asthma exacerbations.


Asunto(s)
Antagonistas de los Receptores Histamínicos H1/farmacología , Molécula 1 de Adhesión Intercelular/biosíntesis , Loratadina/farmacología , Mucosa Respiratoria/efectos de los fármacos , Mucosa Respiratoria/virología , Rhinovirus/crecimiento & desarrollo , Asma/etiología , Bronquios/citología , Bronquios/efectos de los fármacos , Bronquios/virología , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Células Epiteliales/virología , Células HeLa , Humanos , Molécula 1 de Adhesión Intercelular/genética , Loratadina/análogos & derivados , FN-kappa B/metabolismo , Regiones Promotoras Genéticas , Mucosa Respiratoria/citología , Activación Transcripcional , Regulación hacia Arriba/efectos de los fármacos
18.
J Invest Dermatol ; 116(5): 778-84, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11348470

RESUMEN

The activation of the proteolytic plasminogen activator system is important for the re-epithelialization of skin wounds. Keratinocytes synthesize and secrete the urokinase-type plasminogen activator, which binds to its specific receptor on keratinocytes. Receptor-bound urokinase-type plasminogen activator efficiently activates cell surface bound plasminogen. This results in pericellular proteolysis, which facilitates keratinocyte migration. Urokinase-type plasminogen activator activity is specifically controlled by plasminogen activator inhibitor-1 and -2. As retinoids have been reported to accelerate epithelialization of skin wounds in animal studies and clinical settings, we investigated the effects of all-trans retinoic acid on the plasminogen activator system in human epidermal keratinocytes. As tested in a chromogenic plasminogen activation assay, incubation with 10 microM all-trans retinoic acid caused a marked induction of cell-associated plasminogen activity after 24 h, and this induction was blocked by neutralizing anti-urokinase-type plasminogen activator antibodies, but not anti-tissue-type plasminogen activator antibodies. All-trans retinoic acid lead to a strong increase in urokinase-type plasminogen activator (enzyme-linked immunosorbent assay) and urokinase-type plasminogen activator receptor cell surface expression (flow cytometry) after 24 h. At this time-point, tissue-type plasminogen activator and plasminogen activator inhibitor-1 and -2 proteins were not or only slightly increased. Northern blot analyses revealed that all-trans retinoic acid caused an early and short-lived increase of plasminogen activator inhibitor-1, but a prolonged induction of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor mRNA levels. Collectively, these data suggest that all-trans retinoic acid activates the plasminogen activator system in human epidermal keratinocytes by differentially regulating activating and inhibiting components. The activation of the plasminogen activator system may be one mechanism by which all-trans retinoic acid exerts beneficial effects in cutaneous wound healing.


Asunto(s)
Epidermis/efectos de los fármacos , Epidermis/metabolismo , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Activadores Plasminogénicos/metabolismo , Tretinoina/farmacología , Células Cultivadas , Células Epidérmicas , Humanos , Inhibidor 1 de Activador Plasminogénico/genética , Inhibidor 2 de Activador Plasminogénico/genética , ARN Mensajero/metabolismo , Receptores de Superficie Celular/genética , Receptores de Superficie Celular/metabolismo , Receptores del Activador de Plasminógeno Tipo Uroquinasa , Regulación hacia Arriba , Activador de Plasminógeno de Tipo Uroquinasa/genética , Activador de Plasminógeno de Tipo Uroquinasa/metabolismo
20.
J Allergy Clin Immunol ; 105(2 Pt 1): 318-26, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10669853

RESUMEN

BACKGROUND: Rhinoviruses are associated with the majority of asthma exacerbations. To date, the pathogenesis of virus-induced asthma exacerbations is still unclear, and no safe effective therapy is available. Intercellular adhesion molecule-1 (ICAM-1) has a central role in inflammatory cell recruitment to the airways in asthma and is the receptor for 90% of rhinoviruses. We have previously shown that rhinovirus infection of lower airway epithelium induces ICAM-1 expression by a transcriptional mechanism that is critically nuclear factor-kappaB-dependent. OBJECTIVE: The purpose of this study was to investigate the effect of systemic (hydrocortisone [HC], dexamethasone [DM]) and topical (mometasone furoate [MF]) corticosteroids on rhinovirus-induced ICAM-1 up-regulation. METHODS: Cultured primary bronchial or transformed (A549) respiratory epithelial cells were pretreated with corticosteroids for 16 hours and infected with rhinovirus type 16 for 8 hours. ICAM-1 surface expression was evaluated by flow cytometry. In A549 cells ICAM-1 messenger RNA was evaluated by specific reverse transcription-PCR and promoter activation by chloramphenicol acetyltransferase assay. RESULTS: We observed inhibition of rhinovirus-induced ICAM-1 up-regulation with corticosteroid pretreatment in both primary bronchial epithelial and A549 cells. In A549 cells systemic and topical corticosteroids demonstrated a dose-dependent inhibition with similar efficacy (inhibitory concentration 50% 10(-10) mol/L, 10(-11) mol/L, and 10(-11) mol/L for HC, DM, and MF respectively). MF also inhibited ICAM-1 messenger RNA induction by rhinovirus infection in a dose-dependent manner. MF completely inhibited rhinovirus-induced ICAM-1 promoter activation. HC, DM, and MF had no direct effect on rhinovirus infectivity and replication in cultured cells. CONCLUSION: Corticosteroids decrease rhinovirus-induced ICAM-1 up-regulation in respiratory epithelial cells and modulate pretranscriptional mechanisms. This effect may be important for the therapeutic control of virus-induced asthma exacerbations.


Asunto(s)
Corticoesteroides/farmacología , Células Epiteliales/efectos de los fármacos , Molécula 1 de Adhesión Intercelular/biosíntesis , Pulmón/efectos de los fármacos , Regiones Promotoras Genéticas/efectos de los fármacos , Rhinovirus/inmunología , Regulación hacia Arriba/efectos de los fármacos , Línea Celular Transformada , Células Epiteliales/metabolismo , Células Epiteliales/virología , Humanos , Inmunosupresores/farmacología , Molécula 1 de Adhesión Intercelular/genética , Pulmón/citología , Pulmón/metabolismo , Pulmón/virología , Regiones Promotoras Genéticas/inmunología , ARN Mensajero/biosíntesis , ARN Mensajero/genética , ARN Mensajero/metabolismo , Rhinovirus/efectos de los fármacos , Rhinovirus/patogenicidad , Activación Transcripcional/efectos de los fármacos , Activación Transcripcional/inmunología , Regulación hacia Arriba/inmunología , Replicación Viral/efectos de los fármacos , Replicación Viral/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...